6MW 3511
Alternative Names: 6MW-3511Latest Information Update: 25 Apr 2023
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Oct 2022 Mabwell (Shanghai) Bioscience plans a phase I/II trial for Solid tumours (NCT05524194)
- 16 Jun 2022 Preclinical trials in Solid tumours in China (Parenteral) before June 2022
- 16 Jun 2022 The National Medical Products Administration (NMPA) of China approves IND application for 6MW 3511 in Solid tumours